Identification and Study of the Action Mechanism of Small Compound That Inhibits Replication of Respiratory Syncytial Virus

Author:

Shtro Anna A.1,Klabukov Artem M.1ORCID,Garshinina Anzhelika V.1,Galochkina Anastasia V.1,Nikolaeva Yulia V.1,Khomenko Tatyana M.2,Bobkov Danila E.13,Lozhkov Aleksey A.1ORCID,Sivak Konstantin V.1ORCID,Yakovlev Kirill S.1ORCID,Komissarov Andrey B.1,Borisevich Sophia S.4ORCID,Volcho Konstantin P.2ORCID,Salakhutdinov Nariman F.2

Affiliation:

1. Smorodintsev Research Institute of Influenza, Professora Popova str, 15/17, 197376 St. Petersburg, Russia

2. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Acad. Lavrentyev av. 9, 630090 Novosibirsk, Russia

3. Institute of Cytology Russian Academy of Science, Tikhoretsky av., 4, 194064 St. Petersburg, Russia

4. Ufa Chemistry Institute of the Ufa Federal Research Center, 71 Octyabrya pr., 450054 Ufa, Russia

Abstract

Respiratory syncytial virus (RSV) is known to cause annual epidemics of respiratory infections; however, the lack of specific treatment options for this disease poses a challenge. In light of this, there has been a concerted effort to identify small molecules that can effectively combat RSV. This article focuses on the mechanism of action of compound K142, which was identified as a primary screening leader in the earlier stages of the project. The research conducted demonstrates that K142 significantly reduces the intensity of virus penetration into the cells, as well as the formation of syncytia from infected cells. These findings show that the compound’s interaction with the surface proteins of RSV is a key factor in its antiviral activity. Furthermore, pharmacological modeling supports that K142 effectively interacts with the F-protein. However, in vivo studies have shown only weak antiviral activity against RSV infection, with a slight decrease in viral load observed in lung tissues. As a result, there is a need to enhance the bioavailability or antiviral properties of this compound. Based on these findings, we hypothesize that further modifications of the compound under study could potentially increase its antiviral activity.

Funder

Russian Science Foundation

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference16 articles.

1. Global Burden of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children: A Systematic Review and Meta-Analysis;Nair;Lancet,2010

2. Systematic Review of the Biology and Medical Management of Respiratory Syncytial Virus Infection;Black;Respir Care,2003

3. (2023, July 10). Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine.

4. (2023, July 10). Available online: https://www.fda.gov/vaccines-blood-biologics/abrysvo.

5. Khomenko, T.M., Shtro, A.A., Galochkina, A.V., Nikolaeva, Y.V., Petukhova, G.D., Borisevich, S.S., Korchagina, D.V., Volcho, K.P., and Salakhutdinov, N.F. (2021). Monoterpene-Containing Substituted Coumarins as Inhibitors of Respiratory Syncytial Virus (Rsv) Replication. Molecules, 26.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3